{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:51Z","timestamp":1792180671329,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T00:00:00Z","timestamp":1288051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> Adjuvant chemoradiation has become a standard of care in the USA. We evaluated the efficacy and toxicity of adjuvant chemoradiation versus chemotherapy in completely resected locally advanced gastric cancer.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Patients with stage IIIA, IIIB and IV (without metastasis) gastric cancer were treated with chemoradiation and 5\u2010fluorouracil\/cisplatin (FP) (arm A) or FP (arm B). Arm A consisted of one cycle of FP followed by 4500\u2003cGY to radiation field with capecitabine. One month after completion of radiotherapy, patients received three additional cycles of FP every 3\u2003weeks. Arm B consisted of six cycles of FP.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> A total of 61 patients were enrolled, of whom 31 were placed in arm A and 30 in arm B. The median follow\u2010up duration was 77.2\u2003months (range 24\u201392.8\u2003months). We did not find any difference in 3\u2010year disease\u2010free survival between arm A and B (80.0 <jats:italic>vs<\/jats:italic> 75.2%, respectively; <jats:italic>P<\/jats:italic>\u2003=\u20030.887). There was no significant difference between the arms in 5\u2010year disease\u2010free survival (76.7 <jats:italic>vs<\/jats:italic> 59.1%, respectively; <jats:italic>P<\/jats:italic>\u2003=\u20030.222) or overall survival (70.1 <jats:italic>vs<\/jats:italic> 70.0%, respectively; <jats:italic>P<\/jats:italic>\u2003=\u20030.814). Seven patients (22.6%) relapsed in arm A and 12 patients (40%) relapsed in arm B. Grade 3\/4 neutropenia occurred in 48.5% of patients in arm A and 22.9% in arm B. Grade 3 nausea or vomiting occurred in 6% in arm A and 14.6% in arm B.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.<\/jats:p>","DOI":"10.1111\/j.1743-7563.2010.01331.x","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T11:59:40Z","timestamp":1288094380000},"page":"278-285","source":"Crossref","is-referenced-by-count":50,"title":["Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection"],"prefix":"10.1111","volume":"6","author":[{"given":"Hyuk\u2010Chan","family":"KWON","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Chan","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Han","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"JANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"OH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Hyun","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung A.","family":"KWON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suee","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Sik","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo\u2010Jin","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2009.41.3.122"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.593"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318074e351"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0245"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf040"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm536"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010187"},{"key":"e_1_2_7_10_2","first-page":"15s","article-title":"Chemoradiation of resected gastric cancer: a 10\u2010year follow\u2010up of the phase III trial INT0116 (SWOG 9008). Abstract 4515","volume":"27","author":"Macdonald JS","year":"2009","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4_10"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.049"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<553::AID-CNCR2>3.0.CO;2-D"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03026-2"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601311"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.01.001"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj052"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.05.005"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318178d23a"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","unstructured":"LeeJ KangW LimDet\u2003al.Phase III trial of adjuvant capecitabine\/cisplatin (XP) compared with capecitabine\/cisplatin\/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): safety analysis): safety analysis.2009Abstract 5. Proc 2009 Gastrointestianl Cancers Symposium.","DOI":"10.1200\/jco.2009.27.15_suppl.4537"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn717"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-7563.2010.01331.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-7563.2010.01331.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:21:45Z","timestamp":1697404905000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-7563.2010.01331.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,26]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1743-7563.2010.01331.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01331.x","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,26]]}}}